PD-L1 (CD274 molecule)

This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.


Reference: www.ncbi.nlm.nih.gov/gene/29126

Assay type: Immunohistochemistry (IHC)
What is analyzed: Semi-quantitative detection of human PD-L1 protein
Platform: VENTANA Benchmark Ultra, DAKO Autostainer Link48
Kit/antibody: VENTANA PD-L1 (SP142) Assay, VENTANA PD-L1 (SP263) Assay, Agilent PD-L1 IHC 22C3 pharmDx, Agilent PD-L1 IHC 28-8 pharmDx
Tissue Type: Various solid tumours
Required material: FFPE tissue